While there aren’t many widely-used digital therapeutics in gastroenterology yet, there are many other tehnologies like virtual reality that are growing more and more popular in the field, said Sravanthi Parasa, MD, gastroenterologist at Swedish Gastroenterology.
Author: Praveen Suthrum
Sascha Roth remembers the phone call came on a hectic Friday evening. She was racing around her home in Washington, D.C., to pack for New York, where she was scheduled to undergo weeks of radiation therapy for rectal cancer. But the phone call from Memorial Sloan Kettering Cancer Center (MSK) medical oncologist Andrea Cercek changed everything, leaving Sascha “stunned and ecstatic — I was so happy.” Dr. Cercek told Sascha, then 38, that her latest tests showed no evidence of cancer, after Sascha had undergone six months of treatment as the first patient in a clinical trial involving immunotherapy at MSK.
Private equity firms have long used ASCs as investment vehicles, which they have wrapped into larger portfolios and marketed to pension funds and other big institutional investors. But across the market, those institutions are reaching their capacity for such investments.
The GI industry hit a milestone in May with the first FDA approved treatment for eosinophilic esophagitis. The treatment, Dupixent, was approved to treat eosinophilic esophagitis in adults and pediatric patients 12 and older weighing at least 88 pounds. Marc Rothenberg, MD, PhD, director of the Cincinnati Center for Eosinophilic Diseases at Cincinnati Children’s, spoke with Becker’s on June 8 to discuss the approval of the first eosinophilic esophagitis treatment, its significance and the challenges that came with researching the disease.
Based on data from the National Health and Nutrition Examination Survey, celiac disease affects an estimated 0.7% of the population in the United States.1 Findings have shown an increasing prevalence of the disease in both children and adults, which may be partly due to improvements in screening and diagnostic efforts. Studies have also demonstrated various extragastric conditions in this patient population, including dermatologic and neurologic disorders.
GI Dynamics today announced the results of a study of its EndoBarrier system that met efficacy and safety endpoints. Boston-based GI Dynamics designed its EndoBarrier endoscopically delivered device therapy as a non-surgical, alternative treatment for type 2 diabetes and obesity for patients who do not have adequate control of their conditions through their current medication and lifestyle.
DENVER—A program of preoperative bowel stimulation via the efferent limb of the ileostomy significantly reduced rates of postoperative ileus in patients undergoing elective loop ileostomy closure, according to results from a multicenter, single-blind randomized trial.
Speaking on the first day of NHS ConfedExpo, Dr Karen DeSalvo spoke about Google’s vision for the future of healthcare including how the company can help by “aggregating data by making it more interoperable and then providing insights”. Questions surrounding trust were also raised with DeSalvo saying it [trust] was ‘job one’ when it comes to practicing medicine.
Persistent abdominal pain may be caused by a whole range of different conditions, say French experts who call for more physician awareness to achieve early diagnosis and treatment so as to improve patient outcomes.
Here are six colonoscopy and endoscopy updates Becker’s has reported on since May 5: 1. The FDA cleared the first 360-degree colonoscope, Saneso’s colonoscope. 2. Gastric endoscopy patients who use cannabis require higher levels of sedation than non-users, research presented during Digestive Disease Week found.